MED On PubPhys: open In the literature: partially resolved Compiled by AI, not yet reviewed by an editor

Accelerator production routes for therapeutic alpha emitters

55

No. 498 in all physics · No. 21 in Medical and Radiation Physics

Non-expert version

Determine the optimal production route for Ac-225 and related $\alpha$ emitters by measuring excitation functions and co-produced impurities for proton spallation of thorium-232, photonuclear production from Ra-226, and deuteron or $\alpha$ routes, in the energy ranges used by available accelerators. Key figure of merit: yield per beam hour at required radionuclidic purity, in particular Ac-227 contamination. An answer is cross sections and yields fixing the preferred route.

What would settle it

Measured excitation functions and target tests reporting yield and impurity levels for each route.

Status in the literature

Accelerator routes expanded supply after about 2018 while impurity control and scale-up remained limiting.

No solutions, ideas or subproblems yet.

How results are checked

Comments (0)

Comments are not records: they are not signed, stamped or logged. How comments work

No comments yet.

Sign in to comment.

Details, signature and history
Kind
Well-posed question
Answer
Value
Posed
2010
Topic review
Sgouros, Bodei, McDevitt and Nedrow, Radiopharmaceutical therapy in cancer: clinical advances and challenges, Nature Reviews Drug Discovery, 2020. Link
Record
Revision 1 · imported from the seed collection · compiled by AI, not yet reviewed by an editor

Proof

Fingerprint
fc9752740fad…
Public log
Entry 1,722, in checkpoint 2,123
In the log by
Block 969,698, 2026-10-03

This text was in the PubPhys log by that date. The date says nothing about when the problem was first posed.

History